The CCOs successfully modeled cardiac hypertrophy by exhibiting thickened chamber walls, reduced fractional shortening, and increased myofibrillar disarray upon treatment with endothelin-1 (EDN1). Here, EDN1 is linked to cardiac hypertrophy.